This is the authors' abstract. We don't add key points for this paper.
Asthma is a frequent disease affecting more than 22 million adults in the United States.1 It is associated with substantial morbidity and costs,2 with a high spending among patients with severe disease. A central pathological feature of severe and fatal asthma is mucus dysfunction.3 More than 6 decades ago, deaths were attributed to airway-occluding mucus plugs in a case series of fatal asthma.4 Subsequent imaging studies have shown that mucus plugs affect up to 58% of patients with severe asthma and 41%-67% of individuals with chronic obstructive pulmonary disease (COPD).3,5,6 In both conditions, mucus plugs are associated with lower FEV1 and more rapid decline of lung function, highlighting their key role in the obstructive pathophysiology of chronic airway diseases.7–9 Although the causes of mucus plug formation are likely multifactorial, the process involves a complex disruption of biological pathways leading to abnormal mucus and its clearance. Under normal conditions, mucus is mostly composed primarily of water, with 2%-3% solids. Its characteristic viscoelastic properties derive from mucins—large polymeric glycoproteins that form gels. Changes in mucus composition and viscoelasticity can result in pathologic mucus. In patients with asthma, sputum typically contains elevated concentrations of the mucins MUC5AC and MUC5B, with a relative increase of the former. In small airways—bronchioles—MUC5AC also predominates in mucus plugs, consistent with an increased number and size of goblet cells in airway epithelium.10 Because MUC5AC has a more branched structure, it makes the mucus stickier and more viscous.(PMID 41317963) IL-13, a type 2 (T2) inflammatory cytokine, induces a mucosecretory pattern in the airway epithelium, involving an increased MUC5AC gene expression and release.11 Recent studies have shown that MUC5AC mucin promotes tethering to the epithelium, reducing mucus clearance and contributing to plug formation.12 In this issue of the Journal, Schworer et al. elegantly advance our understanding of the pathogenesis of mucus pathology in the bronchiolar region by integrating morphologic, transcriptomic, and spatial analyses of lung tissue from patients with severe asthma, as well as lung tissues from fatal asthma cases and controls (https://doi.org/10.1164/rccm.202409-1849OC).13 Morphological evaluations of peripheral lung tissues demonstrated a substantial MUC5AC-dominated mucus plug burden and increased MUC5AC mRNA expression in both fatal and severe asthma bronchioles. The degree of luminal obstruction correlated significantly with the magnitude of MUC5AC RNA expression in the surrounding epithelium. Given the lack of MUC5AC in terminal bronchioles, the authors suggest that mucus plugs were likely formed by locally released mucins rather than by migration from more distal airways. The investigators also observed an increase in MUC5AC-expressing goblet cells, accompanied by a loss of surfactant protein B (SFTPB) and secretoglobin family 3A member 2 (SCGB3A2)-expressing distal airway secretory cells (DASCs) in both proximal (0.5-2 mm) and distal bronchioles (<0.5 mm) in fatal and severe asthma. These changes were heterogeneously distributed throughout bronchioles, resembling the “proximalization” pattern described in tobacco-exposed individuals.14 Notably, MUC5AC was spread between, but not co-localized with, SFTPB/SCGB3A2-expressing DASCs, confirming their distinct cell identities. To elucidate the mechanisms underlying bronchiolar proximalization, the authors performed in vitro studies of bronchiolar basal cells. They found that interleukin (IL)-13 suppressed FOXA2, a transcription factor important for regional specification of bronchiolar basal cells, as well as the expression of DASC marker genes (eg, SCGB3A2). IL-13 also induced MUC5AC and other T2 marker genes (POSTN and ALOX15). These findings suggest that T2 cytokine signaling shifts bronchiolar basal cell fate from DASCs differentiation toward MUC5AC-high goblet cells and that suppression of FOXA2 may underlie this T2-driven proximalization phenotype unique to asthma. Spatial transcriptomics analyses of MUC5AC-high regions in excised asthma tissues revealed that these epithelial niches were associated with gene expression patterns consistent with T2-driven proximalization. Specifically, these regions included: (1) Upregulation of MUC5AC and genes associated with MUC5AC-high goblet cells (SPDEF, TFF3, CLCA2); (2) Downregulation of DASCs-defining genes (SCGB3A2, SFTPB) and their regulatory transcription factors (FOXA2, NKX2.1); (3) Upregulation of T2-related genes (POSTN and ALOX15T2); and (4) Upregulation of basal cell (KRT5, KRT15, and TP63) and suprabasal/intermediate cell (SERPINB3, PRSS23) genes. Together, these findings indicate that T2 cytokine signals promote basal cell proliferation and differentiation into suprabasal/intermediate cells, and subsequently goblet cells, rather than DASCs. Multiplex immunohistochemistry further revealed that MUC5AC-high epithelial niches were distributed heterogeneously in bronchiolar epithelia, independent of immune cell localization. The authors propose that asthma bronchioles contain epithelial niches that perpetuate T2-driven remodeling and mucus pathology. This study advances our understanding of mucus plugs formation in asthma. Through the integration of spatial transcriptomic and immune-omics analyses, Schworer et al. provide compelling evidence that epithelial basal cells contribute to mucus dysfunction by proliferating and differentiating into MUC5AC-secreting goblet cells.13 This repatterning suggests that the small airway epithelium adopts a transcriptomic phenotype characteristic of proximal airways, a phenomenon previously described in COPD but now demonstrated in asthma.13,14 Interestingly, Souery et al. recently reported that the large airways of individuals with mucus plugs also display a pattern of elevated IL-13-related gene expression.15 These findings invite further investigations into the signaling pathways driving airway proximalization and raise the possibility that these pathways may offer novel therapeutic approaches. The limitations of this study include that the morphometric studies were restricted to randomly selected subpleural sections rather than stereologically sampled lungs; that patients with fatal and severe asthma had received high-dose acute and long-term corticosteroid, which may modify immune cell gene expression and cell populations; and that mild to moderate asthma was not represented, reflecting the challenge of obtaining lung tissue in this population. This study redefines mucus pathology in patients with severe and fatal asthma as a process rooted in epithelial remodeling and proximalization of distal airways, with IL-13 identified as a key pathway in this process. The findings encourage further investigation into the role of proximalization in airway mucus pathology. Okajima and Diaz drafted the manuscript. Okajima, Lenburg, and Diaz edited and critically revised the manuscript. Okajima, Lenburg, and Diaz revised and approved the final version of the manuscript. Okajima, Lenburg, and Diaz takes full responsibility for the integrity of the work. Supplementary material is available at American Journal of Respiratory and Critical Care Medicine online. Please see the ICMJE disclosure forms, which have been provided as supplementary material. This work was supported by the U.S. National Heart, Lung, and Blood Institute (R01-HL149861, R01-HL164824, R01-HL173017 (to Diaz). An LLM was used to proofread the final manuscript draft.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Okajima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: